CAMBRIDGE, Mass., June 2, 2023
/PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a
biopharmaceutical company with the purpose to better the lives of
people impacted by kidney disease, today announced that
John Butler, Chief Executive
Officer, will present at the Jefferies Healthcare Conference on
Wednesday, June 7, 2023 at
8:30 a.m. ET. In his presentation,
Mr. Butler will discuss recent regulatory updates regarding
vadadustat, Akebia's oral hypoxia-inducible factor prolyl
hydroxylase inhibitor for the treatment of anemia due to chronic
kidney disease for dialysis dependent patients, and the potential
global commercial opportunity for Vafseo®
(vadadustat).
The Jefferies Healthcare Conference will take place June 7-9, 2023, in New
York.
A live webcast of the presentation can be accessed through the
Investors section of Akebia's website at
https://ir.akebia.com. A replay of the webcast will also be
available for approximately 90 days following the conference
through the Investors section of Akebia's website at
https://ir.akebia.com.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated
biopharmaceutical company with the purpose to better the lives of
people impacted by kidney disease. Akebia was founded in 2007 and
is headquartered in Cambridge,
Massachusetts. For more information, please visit our
website at www.akebia.com, which does not form a part of this
release.
About Vadadustat
Vadadustat is an oral hypoxia-inducible factor prolyl
hydroxylase inhibitor designed to mimic the physiologic effect of
altitude on oxygen availability. At higher altitudes, the body
responds to lower oxygen availability with stabilization of
hypoxia-inducible factor, which can lead to increased red blood
cell production and improved oxygen delivery to tissues. Vadadustat
is not approved by the U.S. Food and Drug Administration. Vafseo®
(vadadustat) is approved in Europe
for the treatment of symptomatic anemia due to CKD in adult
patients on chronic maintenance dialysis. In Japan, Vafseo is approved as a treatment for
anemia due to CKD in both dialysis-dependent and non-dialysis
dependent adult patients.
Important Safety Information
For safety information, view the European Summary of Product
Characteristics (SPC/SmPC) for Vafseo® (vadadustat) at
https://ec.europa.eu/health/documents/community-register/2023/20230424158854/anx_158854_en.pdf
and https://products.mhra.gov.uk/.
Akebia Therapeutics Contact
Mercedes Carrasco
Mcarrasco@akebia.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-to-present-at-jefferies-healthcare-conference-301841196.html
SOURCE Akebia Therapeutics